sellWeak cluster of 5
Christopher Yea sold $58k of KALV
CHIEF DEVELOPMENT OFFICER at KalVista Pharmaceuticals, Inc.. 4,331 shares at an average of $13.45, traded Nov 24, 2025, filed Nov 26, 2025.
Warning score
22Value
$58k
4,331 shares
Holdings after
223,508
-2% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
- +15RoleOfficer
- +7Trade size$58k at market
- 0Share of holdings soldSold 1.9% of holdings
- +15Cluster5 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0001691102-25-000006, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Nov 21, 2025 | MOption exercise Common Stock | +3,750 | - | - | 224,714 | Nov 26, 2025 |
| Nov 22, 2025 | MOption exercise Common Stock | +3,125 | - | - | 227,839 | Nov 26, 2025 |
| Nov 24, 2025 | SOpen-market sale Common Stock | -4,331 | $13.45 | $58k | 223,508 | Nov 26, 2025 |
| Nov 21, 2025 | MOption exercise Restricted Stock Unitderivative | -3,750 | $0.00 | $0 | 48,750 | Nov 26, 2025 |
| Nov 22, 2025 | MOption exercise Restricted Stock Unitderivative | -3,125 | $0.00 | $0 | 31,250 | Nov 26, 2025 |
Related signals
Other insiders at KalVista Pharmaceuticals, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 9Weak | KALVsell KalVista Pharmaceuticals, Inc. | Paul K. Audhya CHIEF MEDICAL OFFICER | $83k 5,354 shares | -4% | |
| 0Weak | KALVsell KalVista Pharmaceuticals, Inc. | Paul K. Audhya CHIEF MEDICAL OFFICER | $17k 1,163 shares | -1% | |
| 35Weak | KalVista Pharmaceuticals, Inc. | Benjamin L Palleiko CHIEF EXECUTIVE OFFICER | $120k 7,294 shares | -2% | |
| 22Weak | KalVista Pharmaceuticals, Inc. | Nicole Sweeny Chief Commercial Officer | $51k 3,813 shares | -9% | |
| 23Weak | KalVista Pharmaceuticals, Inc. | Paul K. Audhya CHIEF MEDICAL OFFICER | $71k 5,296 shares | -4% | |
| 36Weak | KalVista Pharmaceuticals, Inc. | Benjamin L Palleiko CHIEF EXECUTIVE OFFICER | $147k 10,940 shares | -3% | |
| 39Weak | KalVista Pharmaceuticals, Inc. | Brian Piekos Chief Financial Officer | $60k 4,471 shares | -30% | |
| 21Weak | KalVista Pharmaceuticals, Inc. | Paul K. Audhya CHIEF MEDICAL OFFICER | $45k 3,075 shares | -2% | |
| 33Weak | KalVista Pharmaceuticals, Inc. | Benjamin L Palleiko CHIEF EXECUTIVE OFFICER | $65k 4,466 shares | -1% | |
| 21Weak | KalVista Pharmaceuticals, Inc. | Christopher Yea CHIEF DEVELOPMENT OFFICER | $39k 2,683 shares | -2% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.